Docoh
Loading...

SNGX Soligenix

News

From Benzinga Pro
Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine
2 Dec 21
News
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
56 Biggest Movers From Yesterday
24 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).
36 Stocks Moving In Tuesday's Mid-Day Session
23 Nov 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide esketamine nasal spray for the treatment of resistant depression in adults.
21 Stocks Moving In Tuesday's Pre-Market Session
23 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement for annual meeting after the market close on Monday.
SNGX: Durable Immunity for RiVax® Vaccine…
22 Nov 21
Penny Stocks
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT
Soligenix Q3 EPS $(0.09) Down From $(0.06) YoY, Sales $200.00K Down From $600.00K YoY
12 Nov 21
Earnings, News
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.09) per share. This is a 50 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $200.00 thousand in sales this
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
1 Nov 21
Biotech, News, Penny Stocks, Health Care, FDA, General
Soligenix Says Thermostable Vaccine Technology Platform To Be Presented At 6th International Conference On Vaccines Research And Development
1 Nov 21
News, FDA, Events
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
30 Stocks Moving in Friday's Pre-Market Session
29 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, General
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.
18 Stocks Moving in Friday's Pre-Market Session
8 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
SNGX: CiVax™ Shows Protective Effects Against SARS-CoV-2 Variant in Non-Human Primates…
29 Sep 21
Penny Stocks
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT
12 Health Care Stocks Moving In Tuesday's After-Market Session
28 Sep 21
Movers
Gainers Geovax Labs (NASDAQ:GOVX) shares rose 46.37% to $6.06 during Tuesday's after-market session. This security traded at a volume of 1.9 million shares come close, making up 75.3% of its average volume over the last 100 days. The company's market cap stands at $38.3 million.
Soligenix Highlights Publication Demonstrating 'Efficacy and Broad Neutralizing Activity' Of Its COVID-19 Vaccine In Non-Human Primates
28 Sep 21
Biotech, General
- Vaccination yields broad neutralizing antibody responses against original strain and Beta, Gamma and Delta variants - Durable response demonstrated against original strain and all variants for several months after
Soligenix Invited To Present At The Cantor Fitzgerald Global Healthcare Conference
27 Sep 21
News, Events
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
Soligenix To Test Synthetic Hypericin In Psoriasis Patients
16 Sep 21
Biotech, News, Penny Stocks, Health Care, General
Soligenix To Advance Synthetic Hypericin Development In Psoriasis; Shares Move Higher
16 Sep 21
Cannabis, Markets, Movers, Trading Ideas
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Sep 21
Movers
Gainers
12 Health Care Stocks Moving In Monday's After-Market Session
13 Sep 21
Movers
Gainers
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
9 Sep 21
Biotech, News, Penny Stocks, Health Care, FDA, Movers, Trading Ideas, General

Press releases

From Benzinga Pro
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
2 Dec 21
Small Cap, Press Releases
PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers
30 Nov 21
Press Releases
New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
12 Nov 21
Earnings, Press Releases
PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
8 Nov 21
Small Cap, Press Releases
PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
4 Nov 21
Small Cap, Press Releases
PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development
1 Nov 21
Small Cap, Press Releases
PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare
Highlights and Insights into Soligenix
13 Oct 21
Press Releases
Dr. Chris Schaber Discusses Soligenix HyBryte(TM) and Thermostabilized VaccinesNew York, New York--(Newsfile Corp. - October 13, 2021) - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst
HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
12 Oct 21
Small Cap, Press Releases
PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
28 Sep 21
Press Releases
PRINCETON, N.J., Sept. 28, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare
Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference
27 Sep 21
Small Cap, Press Releases
PRINCETON, N.J., Sept. 27, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
16 Sep 21
Press Releases
PRINCETON, N.J., Sept. 16, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics
14 Sep 21
Press Releases
Soligenix discusses its contribution to addressing future serious public health threats in a podcastNew York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The COVID-19 pandemic has already cost the
Thinking about buying stock in Torrid Holdings, Cardiff Oncology, Soligenix, Gold Royalty, or Enveric Biosciences?
9 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CURV, CRDF, SNGX, GROY, and ENVB.
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
9 Sep 21
Press Releases
PRINCETON, N.J., Sept. 9, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases